



Press release

Montpellier, France, June 1<sup>st</sup> 2022 – 5:45PM CEST

## Intrasense signs a strategic partnership with Nurea

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions, and Nurea, a leading provider of decision support and diagnostic software for vascular diseases, announce the signing of a partnership that will make Nurea's artificial intelligence solution available to clinicians within the Myrian platform, through the Intrasense AI Hub.

### A new intelligent tool that supports physicians in their decision making

The algorithm developed by Nurea is a cutting-edge CT and MRI imaging tool, allowing the early detection of abnormalities as well as the characterization, evaluation and quantification of vascular problems. Nurea's technology also makes it possible to extract additional data, facilitating better patient management in the event of a stroke.

As part of this partnership, Intrasense is integrating Nurea's PRAEVAorta<sup>®</sup> solution into its XP-Vessel application, specialized in vascular exploration in CT and MRI imaging. XP-Vessel, enriched with Nurea's automated reconstruction tool, will allow to easily and accurately visualize the evolution of an aneurysm. The application will also offer optimized reconstruction and 3D modeling performances.

This partnership provides a new opportunity for Intrasense to further enrich its clinical solutions offering within its AI Hub dedicated to artificial intelligence.

### A partnership for cardiovascular prevention

In France, nearly 3 million people suffer from cardiovascular accidents every year. The Myrian XP-Vessel application, enhanced by Nurea, will provide clinicians with an image analysis and digital simulation tool, enabling optimal patient management and prediction of the evolution of their pathology.

*"Patient care, through prevention and better monitoring, is a priority for Intrasense. By combining our expertise and values and building this unique solution together, our goal is to simplify the life of clinicians by offering them the most advanced technological solutions for a more precise and personalized medicine. We are integrating a new artificial intelligence solution for routine clinical practice," said **Nicolas Raymond, CEO of Intrasense.***

*"Nurea's PRAEVAorta<sup>®</sup> solution saves up to 95% of analysis time, with a pathology quantification. Combined with Intrasense's XP-Vessel application and its image manipulation technology, it offers a new tool to secure the clinician in*



*his diagnosis and saves him a precious time", says Florian Bernard, President and co-founder of Nurea.*

By combining the technological strength of Nurea's tools with Myrian, Intrasense continues to work towards clinical innovation and continuous improvement in the quality of patient care.

#### **About Intrasense**

Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1000 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system. Intrasense has 56 employees among which 16 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and has invested more than 10 million euros in Research & Development since its creation. More information on: [www.intrasense.fr](http://www.intrasense.fr)

#### **About Nurea**

Founded in 2018, Nurea publishes software that automatically analyzes images from CT and MRI scans for the prevention of cardiovascular accidents.

Located in the Bordeaux metropolitan area, one of the most attractive regions in the health and medical technology sector, the young company, winner of the i-Lab competition in 2019, has been supporting an entire international network of healthcare institutions since its creation. Between the worlds of research and medicine, Nurea has contributed to the improvement of rapid screening practices for patients at risk of heart attack and aneurysm rupture. For more information, visit: <https://www.nurea-soft.com/>.

## **Contacts**

#### **Intrasense**

**Anne-Elisabeth Achiri**  
Communications Officer  
Phone: +334 67 13 01 30  
[investisseurs@intrasense.fr](mailto:investisseurs@intrasense.fr)

#### **Nurea**

**Florian Bernard**  
President  
Phone: +336 72 01 95 91  
[contact@nurea-soft.com](mailto:contact@nurea-soft.com)

#### **NewCap**

**Olivier Bricaud**  
Financial communication  
and investor relations  
Phone: +331 44 71 20 40  
[intrasense@newcap.eu](mailto:intrasense@newcap.eu)

